Blog Posts
ICYMI – Law360: How Biotech Deals May Help Competition, Despite FTC View
In a recent commentary for Law 360, biopharma expert Michael Kinch and economists Jee-Yonn Lehmann and Frederico Mantovanelli rightly point out that biopharmaceutical mergers and acquisitions (M&A) and other collaborations play an important role in promoting competition and helping companies of all sizes to innovate more efficiently.
Pro-Innovation M&A Allows Life Sciences Innovators to Weather the Significant Costs of R&D
Life sciences companies of all sizes face extended time and cost pressures as they work to bring new medicines to patients, as the average cost of research and development (R&D) can exceed $2.8 billion, and it can take more than 10-15 years to bring a new therapy to market.
Backgrounder: The Role of M&A Policy in the Life Sciences and its Impacts on Innovation
Mergers and acquisitions allow life sciences companies of all sizes to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Unfortunately, the latest merger guidelines and proposed premerger notification requirements issued by the Federal Trade Commission (FTC) and Department of Justice (DOJ) reflect a misguided approach that will prevent and deter pro-innovation M&A and disrupt our world-class American life sciences ecosystem.
Changes to HSR Premerger Rules Would Add Unnecessary Financial and Operational Barriers to Pro-Innovation M&A
The Hart-Scott-Rodino (HSR) Act requires companies to report information to the Federal Trade Commission (FTC) and Department of Justice (DOJ) before a planned merger or acquisition (M&A). Under the HSR Act, the agencies enforce premerger reporting requirements that merging parties must meet before a transaction can proceed.
An Interview with AZBio President and CEO on Life Sciences M&A in Arizona
PULSE sat down for a conversation with Joan Koerber-Walker, president and CEO of AZBio, which recently celebrated 20 years of supporting the growth of Arizona’s life science industry. PULSE asked Joan for her perspective on how mergers and acquisitions (M&A) have impacted and benefited Arizona’s economic outlook and contributions to the state.
New NAM Report Finds Biopharmaceutical R&D Investment Crucial for Patients, the Economy
In a new report, the National Association of Manufacturers (NAM), a PULSE partner, examines the pharmaceutical industry’s significant commitment to R&D and its impact on our economy and our health.
PULSE Statement on Finalized Joint Merger Guidelines from FTC, DOJ
The Partnership for the U.S. Life Science Ecosystem (PULSE) released the following statement in response to the latest merger guidelines released today by the Federal Trade Commission (FTC) and Department of Justice (DOJ).
Opinion: Proposed regulation would limit life-saving research in Ohio
In a recent op-ed, Ohio Life Sciences President and CEO Eddie Pauline discusses how mergers and acquisitions allow life sciences companies to scale up and provide their research or therapies to patients on a national and global scale.
In Case You Missed It: PULSE Webinar – Life Science M&A: Supporting the Next Generation of Biopharma Breakthroughs
In a recent PULSE webinar, top experts from across the U.S. life sciences ecosystem highlighted the unique importance of mergers and acquisitions (M&A) in bringing new biopharmaceutical breakthroughs to market. The panelists broke down the complex path to market for new treatments and cures, and how M&A is critical in allowing companies of all sizes to combine the necessary resources and expertise to advance these innovations.
The Legislative Pillars Supporting Innovation & Access in the Life Sciences Ecosystem
For nearly four decades, policymakers have prioritized bipartisan policies that incentivize investment in groundbreaking medical research – aiming to make new innovations accessible for millions of Americans.